Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China's Sinovac Sees Profits Plummet In Wake Of Public Fears Following Vaccine Scandals By Other Producers

This article was originally published in PharmAsia News

Executive Summary

BEIJING - China's leading vaccine developer, Sinovac Biotech, posted a steep fall in profits for the second quarter, and revealed that the World Health Organization is working with Chinese regulators on monitoring good manufacturing practice standards following a series of scandals that have hurt the entire sector

You may also be interested in...



Bill Gates Meets With Sinovac Scientists In Beijing: Will They Be Integrated Into Gates Foundation's Global Immunization Drives?

BEIJING - During a whirlwind tour of China, Microsoft founder Bill Gates met with scientists at China's leading vaccine developer, Sinovac Biotech, as the Gates Foundation ramps up a project to supply vaccines to kids in need across the planet

Bill Gates Meets With Sinovac Scientists In Beijing: Will They Be Integrated Into Gates Foundation's Global Immunization Drives?

BEIJING - During a whirlwind tour of China, Microsoft founder Bill Gates met with scientists at China's leading vaccine developer, Sinovac Biotech, as the Gates Foundation ramps up a project to supply vaccines to kids in need across the planet

GSK Channels More Money Into Vaccine Venture With China's Neptunus As Earnings Sink In The West

BEIJING - Despite posting a sizeable loss in earnings for the second quarter of this year, GlaxoSmithKline is pumping new funds into its recently established joint venture in southern China in a move aimed at profiting from China's healthy economic growth despite the financial ailments that have plagued the Western world

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC075666

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel